


This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (withdrawn) A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is (CH<sub>2</sub>)<sub>m</sub>(CH(R<sup>1</sup>))<sub>n</sub>(CH<sub>2</sub>)<sub>p</sub>;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

R<sup>1</sup> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl or C<sub>3-6</sub> alkynyl;

R<sup>2</sup> is hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by hydroxy or C<sub>1-6</sub> alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, OR<sup>6</sup>, CN and methylenedioxy;

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by hydroxy or C<sub>1-6</sub> alkoxy, CF<sub>3</sub>, OR<sup>6</sup>, COR<sup>7</sup>, NHCOR<sup>8</sup>, NHCONHR<sup>8</sup>, NHSO<sub>2</sub>R<sup>8</sup>, CONHR<sup>9</sup>, CN, SO<sub>2</sub>R<sup>8</sup> or NR<sup>10</sup>R<sup>11</sup>;

R<sup>6</sup> is hydrogen, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub> alkynyl, C<sub>1-6</sub> alkyl optionally substituted by hydroxy or C<sub>1-6</sub> alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy and methylenedioxy;

$R^7$  is  $C_{1-6}$  alkyl,  $OR^6$  or phenyl optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy and  $NHCOR^8$ ;

$R^8$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{1-6}$  alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;  $C_{3-6}$  cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from  $NR^{12}$ , S and O; or aryl or heteroaryl<sub>2</sub> wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;

$R^9$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen,  $C_{1-6}$  alkyl,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkoxy and methylenedioxy;

$R^{10}$  and  $R^{11}$  are, independently, hydrogen or  $C_{1-6}$  alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from  $NR^{12}$ , O and S; and

$R^{12}$  is hydrogen or  $C_{1-6}$  alkyl;  
provided that the compound is not:

2-[4-[5-(2,4-dichlorophenyl)furan-2-yl]-1,3-thiazol-2-yl]acetic acid.

2. (withdrawn) A compound according to claim 1 wherein Q is  $CH_2$ .
3. (withdrawn) A compound according to claim 1 wherein  $R^2$  is hydrogen or halogen.

4. (withdrawn) A compound according to claim 1 wherein  $R^3$ ,  $R^4$  and  $R^5$  are, independently, hydrogen, halogen,  $C_{1-6}$  alkyl optionally substituted by hydroxyl or  $C_{1-6}$  alkoxy,  $CF_3$ ,  $OR^6$ ,  $NHCOR^8$  or  $CONHR^9$ , wherein at least one of  $R^3$ ,  $R^4$  and  $R^5$  is other than hydrogen.
5. (withdrawn) A compound according to claim 4 wherein one of  $R^3$  and  $R^4$  is  $NHCOR^8$  and the other is hydrogen or halogen, and  $R^5$  is hydrogen.
6. (withdrawn) A compound according to claim 1 wherein  $R^8$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{1-6}$  alkoxy, any of which is optionally substituted by phenyl, wherein the phenyl is optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;  $C_{3-6}$  cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from  $NR^{12}$ , S and O; phenyl optionally substituted by one or more substituents selected from halogen,  $C_{1-6}$  alkyl,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN and methylenedioxy; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing one to three heteroatoms selected from O, N and S, which heteroaryl group is optionally substituted by  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy or halogen.
7. (withdrawn) A compound according to claim 6 wherein  $R^8$  is  $C_{1-6}$  alkyl or  $C_{2-6}$  alkenyl, either of which is optionally substituted by phenyl, wherein the phenyl is optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$

alkyl, methylenedioxy and  $\text{NR}^{10}\text{R}^{11}$ ; phenyl optionally substituted by one or more substituents selected from halogen,  $\text{C}_{1-6}$  alkyl,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{OR}^6$ , CN and methylenedioxy; or a 5- to 10-membered mono- or bicyclic heteroaryl group containing one to three heteroatoms selected from O, N and S, which heteroaryl group is optionally substituted by  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy or halogen.

8. (withdrawn) A compound according to claim 1 selected from

2-[4-[5-(2,3-Dichlorophenyl)furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[4-(2-Benzyloxyethylcarbamoyl)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(2,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(4-bromo)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(2,4-dichloro)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(3,5-bistrifluoromethyl)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(2-methyl-3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(benzothiophene-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(6-chloro-4H-chromene-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-chlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-bromophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-methylenedioxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-chlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(5-bromopyrindine-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-trifluoromethyl-4-fluorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-cyanophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-methoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(furan-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid, and

2-[4-[5-[2-Chloro-4-[3-(4-methoxy)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

or a pharmaceutically acceptable salt or prodrug thereof.

9. (withdrawn) A compound according to claim 1 selected from:

2-[4-[5-[2-Chloro-4-[(2,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(4-bromo)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(2,4-dichloro)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[3-(3,5-ditrifluoromethyl)phenylacryloylamino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-(3-phenylacryloylamino)phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(benzothiophene-2-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(6-chloro-4H-chromene-3-carbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3,4-dichlorophenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

2-[4-[5-[2-Chloro-4-[(3-methoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid, and


2-[4-[5-[2-Chloro-4-[(4-trifluoromethoxyphenylcarbonyl)amino]phenyl]furan-2-yl]-1,3-thiazol-2-yl]acetic acid,

or a pharmaceutically acceptable salt or prodrug thereof.

10. (canceled)


11. (withdrawn) A process for the preparation of a compound according to claim 1 which comprises:

reacting a compound of formula (II):



(II)

with a compound of formula (III):




(III)

wherein  $R^A$  is H,  $C_{1-6}$  alkyl or a protecting group; optionally followed by deprotection of the group  $OR^A$ , to give the corresponding carboxylic acid.

12. (withdrawn) A process for the preparation of a compound according to claim 1


wherein one or more of  $R^3$ ,  $R^4$  and  $R^5$  is  $NHCO R^8$  which comprises:

reacting a compound of formula (VIII):



(VIII)


wherein one or more of  $R^3$ ,  $R^4$  and  $R^5$  is  $NH_2$ , and  $R^A$  is H,  $C_{1-6}$  alkyl or a protecting group, with a compound of formula (IX):



(IX)

in an amide bond formation reaction.

13. (withdrawn) A pharmaceutical composition comprising a compound according to formula (I) or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

$Q$  is  $(CH_2)_m(CH(R^1))_n(CH_2)_p$ ;

$n$  is 0 or 1;

$m$  and  $p$  are, independently, 0, 1 or 2;

$R^1$  is hydrogen,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-6}$  alkynyl;

$R^2$  is hydrogen, halogen,  $C_{1-6}$  alkyl optionally substituted by hydroxy or  $C_{1-6}$  alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen,  $C_{1-6}$  alkyl,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ ,  $CN$  and methylenedioxy;

$R^3$ ,  $R^4$  and  $R^5$  are, independently, hydrogen, halogen,  $C_{1-6}$  alkyl optionally substituted by hydroxy or  $C_{1-6}$  alkoxy,  $CF_3$ ,  $OR^6$ ,  $COR^7$ ,  $NHCOR^8$ ,  $NHCONHR^8$ ,  $NHSO_2R^8$ ,  $CONHR^9$ ,  $CN$ ,  $SO_2R^8$  or  $NR^{10}R^{11}$ ;

$R^6$  is hydrogen,  $C_{2-6}$  alkenyl,  $C_{3-6}$  alkynyl,  $C_{1-6}$  alkyl optionally substituted by hydroxy or  $C_{1-6}$  alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy and methylenedioxy;

$R^7$  is  $C_{1-6}$  alkyl,  $OR^6$  or phenyl optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy and  $NHCOR^8$ ;

$R^8$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{1-6}$  alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;  $C_{3-6}$  cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from  $NR^{12}$ , S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;


$R^9$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen,  $C_{1-6}$  alkyl,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkoxy and methylenedioxy;

$R^{10}$  and  $R^{11}$  are, independently, hydrogen or  $C_{1-6}$  alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from  $NR^{12}$ , O and S; and

$R^{12}$  is hydrogen or  $C_{1-6}$  alkyl;  
together with a pharmaceutically acceptable carrier or excipient.

14-17. (canceled)

18. (withdrawn) A compound of formula (II):



(II)

wherein

R<sup>2</sup> is hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by hydroxy or C<sub>1-6</sub> alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, OR<sup>6</sup>, CN and methylenedioxy;

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by hydroxy or C<sub>1-6</sub> alkoxy, CF<sub>3</sub>, OR<sup>6</sup>, COR<sup>7</sup>, NHCOR<sup>8</sup>, NHCONHR<sup>8</sup>, NHSO<sub>2</sub>R<sup>8</sup>, CONHR<sup>9</sup>, CN, SO<sub>2</sub>R<sup>8</sup> or NR<sup>10</sup>R<sup>11</sup>;

R<sup>6</sup> is hydrogen, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub> alkynyl, C<sub>1-6</sub> alkyl optionally substituted by hydroxy or C<sub>1-6</sub> alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy and methylenedioxy;

R<sup>7</sup> is C<sub>1-6</sub> alkyl, OR<sup>6</sup> or phenyl optionally substituted by one or more substituents selected from halogen, CF<sub>3</sub>, OCF<sub>3</sub>, CN, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy and NHCOR<sup>8</sup>;


$R^8$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{1-6}$  alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;  $C_{3-6}$  cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from  $NR^{12}$ , S and O; or aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;

$R^9$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen,  $C_{1-6}$  alkyl,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkoxy and methylenedioxy;

$R^{10}$  and  $R^{11}$  are, independently, hydrogen or  $C_{1-6}$  alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from  $NR^{12}$ , O and S; and

$R^{12}$  is hydrogen or  $C_{1-6}$  alkyl.

19. (withdrawn) A compound of formula (X):



(X)

wherein

Q is  $(CH_2)_m(CH(R^1))_n(CH_2)_p$ ;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

$R^1$  is hydrogen,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-6}$  alkynyl;

$R^2$  is hydrogen, halogen,  $C_{1-6}$  alkyl optionally substituted by hydroxy or  $C_{1-6}$  alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen,  $C_{1-6}$  alkyl,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN and methylenedioxy;

$R^6$  is hydrogen,  $C_{2-6}$  alkenyl,  $C_{3-6}$  alkynyl,  $C_{1-6}$  alkyl optionally substituted by hydroxy or  $C_{1-6}$  alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy and methylenedioxy;

$R^A$  is H,  $C_{1-6}$  alkyl, or a protecting group;

$R^3$ ,  $R^4$  and  $R^5$  are, independently, hydrogen, halogen,  $C_{1-6}$  alkyl optionally substituted by hydroxy or  $C_{1-6}$  alkoxy,  $CF_3$ ,  $OR^6$ ,  $COR^7$ ,  $NHCOR^8$ ,  $NHCONHR^8$ ,  $NHSO_2R^8$ ,  $CONHR^9$ , CN,  $SO_2R^8$  or  $NR^{10}R^{11}$ ;

$R^7$  is  $C_{1-6}$  alkyl,  $OR^6$  or phenyl optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ , CN,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy and  $NHCOR^8$ ;

$R^8$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{1-6}$  alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $CF_3$ ,  $OCF_3$ ,  $OR^6$ , CN,  $C_{1-6}$  alkyl, methylenedioxy and  $NR^{10}R^{11}$ ;  $C_{3-6}$  cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from  $NR^{12}$ , S and O; or aryl or heteroaryl, wherein the aryl and

heteroaryl groups are optionally substituted by one or more substituents selected from

halogen, CF<sub>3</sub>, OCF<sub>3</sub>, OR<sup>6</sup>, CN, C<sub>1-6</sub> alkyl, methylenedioxy and NR<sup>10</sup>R<sup>11</sup>;

R<sup>9</sup> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, CN, C<sub>1-6</sub> alkoxy and methylenedioxy;


R<sup>10</sup> and R<sup>11</sup> are, independently, hydrogen or C<sub>1-6</sub> alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR<sup>12</sup>, O and S; and

R<sup>12</sup> is hydrogen or C<sub>1-6</sub> alkyl;

provided that at least one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is NO<sub>2</sub>.

20. (canceled)

21. (currently amended) A method for the ~~treatment~~ therapeutic therapy of colorectal cancer, prostate cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, renal cancer, gastric cancer, bladder cancer or ovarian cancer comprising administering to a patient suffering ~~from cancer~~ therefrom a pharmaceutically effective amount of a compound of formula I or a pharmaceutically acceptable salt or prodrug thereof:



(I)

wherein

Q is  $(\text{CH}_2)_m(\text{CH}(\text{R}^1))_n(\text{CH}_2)_p$ ;

n is 0 or 1;

m and p are, independently, 0, 1 or 2;

$\text{R}^1$  is hydrogen,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl or  $\text{C}_{3-6}$  alkynyl;

$\text{R}^2$  is hydrogen, halogen,  $\text{C}_{1-6}$  alkyl optionally substituted by hydroxy or  $\text{C}_{1-6}$  alkoxy, or phenyl optionally substituted by one or more substituents selected from halogen,  $\text{C}_{1-6}$  alkyl,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{OR}^6$ , CN and methylenedioxy;

$\text{R}^3$ ,  $\text{R}^4$  and  $\text{R}^5$  are, independently, hydrogen, halogen,  $\text{C}_{1-6}$  alkyl optionally substituted by hydroxy or  $\text{C}_{1-6}$  alkoxy,  $\text{CF}_3$ ,  $\text{OR}^6$ ,  $\text{COR}^7$ ,  $\text{NHCOR}^8$ ,  $\text{NHCONHR}^8$ ,  $\text{NHSO}_2\text{R}^8$ ,  $\text{CONHR}^9$ , CN,  $\text{SO}_2\text{R}^8$  or  $\text{NR}^{10}\text{R}^{11}$ ;

$\text{R}^6$  is hydrogen,  $\text{C}_{2-6}$  alkenyl,  $\text{C}_{3-6}$  alkynyl,  $\text{C}_{1-6}$  alkyl optionally substituted by hydroxy or  $\text{C}_{1-6}$  alkoxy, aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $\text{CF}_3$ ,  $\text{OCF}_3$ , CN,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy and methylenedioxy;

$\text{R}^7$  is  $\text{C}_{1-6}$  alkyl,  $\text{OR}^6$  or phenyl optionally substituted by one or more substituents selected from halogen,  $\text{CF}_3$ ,  $\text{OCF}_3$ , CN,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy and  $\text{NHCOR}^8$ ;

$\text{R}^8$  is  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl, or  $\text{C}_{1-6}$  alkoxy, any of which is optionally substituted by aryl or heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by one or more substituents selected from halogen,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{OR}^6$ , CN,  $\text{C}_{1-6}$  alkyl, methylenedioxy and  $\text{NR}^{10}\text{R}^{11}$ ;  $\text{C}_{3-6}$  cycloalkyl, wherein the cycloalkyl ring optionally contains up to two heteroatoms selected from  $\text{NR}^{12}$ , S and O; or aryl or heteroaryl, wherein the aryl and

heteroaryl groups are optionally substituted by one or more substituents selected from

halogen, CF<sub>3</sub>, OCF<sub>3</sub>, OR<sup>6</sup>, CN, C<sub>1-6</sub> alkyl, methylenedioxy and NR<sup>10</sup>R<sup>11</sup>;

R<sup>9</sup> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkylphenyl, or phenyl, wherein the alkyl groups are optionally interrupted by oxygen and wherein the phenyl groups are optionally substituted by one or more substituents selected from halogen, C<sub>1-6</sub> alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, CN, C<sub>1-6</sub> alkoxy and methylenedioxy;

R<sup>10</sup> and R<sup>11</sup> are, independently, hydrogen or C<sub>1-6</sub> alkyl, or together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclic group which optionally contains an additional heteroatom selected from NR<sup>12</sup>, O and S; and

R<sup>12</sup> is hydrogen or C<sub>1-6</sub> alkyl.

22-27. (canceled)